Form 8-K - Current report:
SEC Accession No. 0000950142-22-001844
Filing Date
2022-06-08
Accepted
2022-06-08 07:59:18
Documents
15
Period of Report
2022-06-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K eh220259882_8k.htm   iXBRL 8-K 33017
2 EXHIBIT 99.1 eh220259882_ex9901.htm EX-99.1 11952
3 GRAPHIC company_logo.jpg GRAPHIC 10406
  Complete submission text file 0000950142-22-001844.txt   277909

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nrxp-20220606.xsd EX-101.SCH 3690
5 XBRL DEFINITION FILE nrxp-20220606_def.xml EX-101.DEF 26608
6 XBRL LABEL FILE nrxp-20220606_lab.xml EX-101.LAB 36687
7 XBRL PRESENTATION FILE nrxp-20220606_pre.xml EX-101.PRE 25232
9 EXTRACTED XBRL INSTANCE DOCUMENT eh220259882_8k_htm.xml XML 5562
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 221002610
SIC: 2834 Pharmaceutical Preparations